Systematic review and meta-analysis: Use of statins is associated with a reduced incidence of oesophageal adenocarcinoma

Thomas, Tom, Loke, Yoon and Beales, Ian L. P. (2018) Systematic review and meta-analysis: Use of statins is associated with a reduced incidence of oesophageal adenocarcinoma. Journal of Gastrointestinal Cancer, 49 (4). 442–454. ISSN 1941-6628

Preview

PDF (Published manuscript) - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Purpose: Laboratory studies have suggested that statins may have useful anti-cancer effects against Barrett’s epithelial cancer lines. A variety of effects have been reported in clinical studies. Methods: We performed a systematic review and meta-analysis of the association between statin use and the development of oesophageal cancer. Multiple databases were searched for studies reporting the association of statin use and oesophageal cancer. Meta-analysis on the relationship between statin use and cancer incidence was performed. Results: Twenty publications met eligibility criteria, yielding 22 datasets for meta-analysis. All were observational studies. Population-level studies included 372,206 cancer cases and 6,086,906 controls. Studies examining adenocarcinoma development in Barrett’s oesophagus included 1057 cancers and 17,741 controls. In patients with Barrett’s oesophagus, statin use was associated with a reduced incidence of adenocarcinoma (pooled adjusted odds ratio (OR) 0.59 (95% confidence intervals 0.50–0.68)), with no heterogeneity between 11 studies. Population-based studies demonstrated more heterogeneity but showed that statin use was associated with a lower incidence of both oesophageal adenocarcinoma (OR 0.57 (0.43–0.76)) and all oesophageal cancers (OR 0.82 (0.7–0.88)). Information on statin type, dose, and duration was reported too infrequently for statistical analysis but individual studies showed a tendency to a dose- and duration-dependant decrease in cancer incidence. Conclusions: Statin use is associated with a significantly lower incidence of oesophageal adenocarcinoma. This is seen in both Barrett’s cohorts and general populations. Further studies should focus on drug, dose, and duration and the interaction with other risk and preventative factors.

Item Type:	Article
Uncontrolled Keywords:	barrett’s oeosphagus,chemoprevention,cancer risk,oesophageal carcinoma,statins,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Health Services and Primary Care Faculty of Science > Research Groups > Norwich Epidemiology Centre Faculty of Medicine and Health Sciences > Research Groups > Norwich Epidemiology Centre Faculty of Medicine and Health Sciences > Research Centres > Population Health Faculty of Medicine and Health Sciences > Research Centres > Lifespan Health
Related URLs:	http://link.springer.com/10.1007/s12029-...
Depositing User:	Pure Connector
Date Deposited:	18 Jul 2017 05:06
Last Modified:	06 Jun 2024 14:58
URI:	https://ueaeprints.uea.ac.uk/id/eprint/64135
DOI:	10.1007/s12029-017-9983-0

Downloads

Actions (login required)

View Item